| pubmed-article:18798551 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0150369 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0334634 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0242596 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0174680 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C2698872 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0679250 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0017262 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0392762 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C2911684 | lld:lifeskim |
| pubmed-article:18798551 | lifeskim:mentions | umls-concept:C0185117 | lld:lifeskim |
| pubmed-article:18798551 | pubmed:issue | 12 | lld:pubmed |
| pubmed-article:18798551 | pubmed:dateCreated | 2008-12-16 | lld:pubmed |
| pubmed-article:18798551 | pubmed:abstractText | In mantle cell lymphoma (MCL), minimal residual disease (MRD) is an indicator of the disease outcome. Quantitative methods used so far do not provide a suitable molecular marker in 30-70% patients with MCL (depending on the technique used). We tested cyclin D1 as a marker for quantitative MRD monitoring. The real-time PCR of cyclin D1 mRNA was performed in 144 bone marrow (BM) specimens including 95 BMs from MCL patients, 39 BMs from patients with other B-cell non-Hodgkin's lymphomas and 10 BMs from healthy volunteer donors. In 73 BMs obtained from 20 MCL patients we examined the cyclin D1 level during the treatment and follow-up period. We detected a cyclin D1 overexpression exclusively in BMs infiltrated with MCL, including minimal residual infiltration. Dynamics of cyclin D1 correlated with the patient's clinical status in 69/73 BMs. Individual monitoring of patients during the disease course showed cyclin D1 quantitative changes accompanying either the disease relapse or a successful treatment response or the disease-free survival (remission) and it showed a predictive significance. Cyclin D1 detection is a promising approach for the quantitative MRD monitoring in MCL patients, and the individual monitoring of the cyclin D1 dynamics represents a suitable indicator of the disease course. | lld:pubmed |
| pubmed-article:18798551 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18798551 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18798551 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18798551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18798551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18798551 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18798551 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18798551 | pubmed:month | Dec | lld:pubmed |
| pubmed-article:18798551 | pubmed:issn | 1097-0215 | lld:pubmed |
| pubmed-article:18798551 | pubmed:author | pubmed-author:KodetRomanR | lld:pubmed |
| pubmed-article:18798551 | pubmed:author | pubmed-author:KalinovaMarke... | lld:pubmed |
| pubmed-article:18798551 | pubmed:author | pubmed-author:MrhalovaMarce... | lld:pubmed |
| pubmed-article:18798551 | pubmed:author | pubmed-author:KrskovaLenkaL | lld:pubmed |
| pubmed-article:18798551 | pubmed:author | pubmed-author:BrizovaHelena... | lld:pubmed |
| pubmed-article:18798551 | pubmed:copyrightInfo | (c) 2008 Wiley-Liss, Inc. | lld:pubmed |
| pubmed-article:18798551 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18798551 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:18798551 | pubmed:volume | 123 | lld:pubmed |
| pubmed-article:18798551 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18798551 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18798551 | pubmed:pagination | 2865-70 | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:meshHeading | pubmed-meshheading:18798551... | lld:pubmed |
| pubmed-article:18798551 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18798551 | pubmed:articleTitle | Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma. | lld:pubmed |
| pubmed-article:18798551 | pubmed:affiliation | Department of Pathology and Molecular Medicine, 2nd Medical School, Charles University in Prague, and Faculty Hospital in Motol, Prague, Czech Republic. helena.brizova@fnmotol.cz | lld:pubmed |
| pubmed-article:18798551 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18798551 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:595 | entrezgene:pubmed | pubmed-article:18798551 | lld:entrezgene |
| http://linkedlifedata.com/r... | entrezgene:pubmed | pubmed-article:18798551 | lld:entrezgene |
| lhgdn:association:21956 | lhgdn:found_in | pubmed-article:18798551 | lld:lhgdn |
